Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Withdrawn 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2Lymphoid 1

Conditions

Multiple Myeloma 20Neoplasms, Plasma Cell 4Recurrence 2Infections 1

Interventions

Dexamethasone 109pomalidomide 53Cyclophosphamide 52Bortezomib 42fludarabine phosphate 33Lenalidomide 33Peripheral Blood Stem Cell Transplantation 28carfilzomib 26Mycophenolic Acid 25daratumumab 24Calcium Dobesilate 24Cyclosporine 22Busulfan 21Antilymphocyte Serum 20Tacrolimus 19Whole-Body Irradiation 18Melphalan 17Radiotherapy 15Filgrastim 15Methotrexate 14fludarabine 12Methylprednisolone 12elotuzumab 11Cord Blood Stem Cell Transplantation 11selinexor 10ixazomib 9Etoposide 8Thalidomide 7Prednisone 7Panobinostat 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recurrence × Clarithromycin × Plasma cell × Clear all
NCT02343042 2026-05-04

STOMP

Karyopharm Therapeutics Inc

Phase 1/2 Active not recruiting
300 enrolled
Plasma cell

Multiple Myeloma, Recurrence

NCT02986451 2018-08-14

Clarithromycin,Lenalidomide and Dexamethasone for Relapsed/Refractory Myeloma

Sun Yat-sen University

Phase 2 Withdrawn
Plasma cell

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡